Reading time approx. 9 min
Medical cannabis is once again under political pressure in 2026.
Telemedical prescriptions and the shipping of cannabis flowers are set to be restricted – though nothing has been decided yet.
At the same time, private cultivation for adults remains a distinct part of the German cannabis reality.
Could this bring home growing back into the spotlight?
Status: August 22, 2026
The planned changes to the Medical Cannabis Act have not yet come into force. The government draft is still in the parliamentary process.
Cannabis by prescription under pressure: Will home growing become more important again?
What is being planned for telemedicine, cannabis flowers, and shipping – and why private cultivation could move more into the cultural focus as a result.
A few details.
An online questionnaire.
A privately issued medical prescription.
A few days later, medical cannabis arrives by mail.
Since cannabis was removed from the Narcotics Act in April 2024, a new market has developed in Germany in a surprisingly short time. Telemedicine providers are competing for patients, specialized pharmacies are shipping cannabis flowers nationwide, and access to a private prescription has, in some cases, become significantly easier than before.
It is precisely this development that is now up for political debate.
Federal Health Minister Nina Warken intends to tighten the rules for the prescription and dispensing of medical cannabis flowers. The current government draft includes, among other things, a requirement for personal doctor-patient contact for the initial prescription and a ban on pharmacy shipping of cannabis flowers.
However, this has not yet been decided.
And that is exactly what makes the situation in the summer of 2026 so interesting.
For while there is a struggle over medical cannabis, telemedicine, and shipping, another part of German cannabis legislation remains untouched so far:
Private cultivation for adults.
This could clarify a distinction that has partly blurred over the past two years.
Cannabis as medicine on one side.
Cannabis as a privately grown plant, genetics, and part of a new home-growing culture on the other.
Cannabis prescription 2026 at a glance
Planned
Personal doctor-patient contact for the initial prescription of cannabis flowers and restrictions on follow-up prescriptions.
Shipping
Under the government draft, cannabis flowers would no longer be allowed to be regularly shipped by mail-order pharmacies.
Not yet decided
As of August 22, 2026, the planned changes are not in effect. The process is still ongoing.
Home growing
Private cultivation under the Consumption Cannabis Act is not currently being revoked by the discussed amendment to the Medical Cannabis Act (MedCanG).
What is supposed to change regarding medical cannabis?
The current government draft to amend the Medical Cannabis Act is primarily directed against a development that the Federal Ministry of Health views as problematic.
Since the new regulations of 2024, access to medical cannabis has become significantly easier.
Cannabis is no longer a controlled substance. At the same time, numerous telemedical services have emerged through which patients can receive digital consultations.
The federal government now wants to restrict these options for cannabis flowers more strictly again.
The draft primarily contains two major changes.
Personal doctor contact for the initial prescription
According to the federal government's plans, an initial prescription for cannabis flowers should generally only be possible after a personal meeting between a doctor and a patient.
That is, in a clinic or as part of a home visit.
For follow-up prescriptions, at least one such personal contact must have taken place within four quarters. In the remaining quarters, telemedical follow-up prescriptions would subsequently be possible.
This would significantly restrict remote-only prescribing.
Shipping of cannabis flowers to be eliminated
The second planned change would be even more drastic.
Under the government draft, cannabis flowers should no longer be allowed to be regularly shipped by mail-order pharmacies.
The Federal Ministry of Health justifies this with the special advisory and information obligations surrounding medical cannabis.
Pharmacy courier services, however, are intended to remain possible.
If this regulation is indeed passed in this form, the currently known processes of many telemedicine providers would change significantly.
Is telemedicine for cannabis soon to be banned?
No – at least not yet.
This is currently probably the most important piece of information.
The draft was first discussed in the Bundestag on December 18, 2025, and subsequently referred to the relevant committees. The public hearing in the Health Committee took place on January 14, 2026. A final second and third reading has not yet been documented.
The current legal status therefore remains in place for the time being.
Anyone currently reading headlines like "Telemedicine for cannabis to be banned" or "Cannabis shipping on the brink" should distinguish between two things:
What is politically planned – and what is already current law.
That is not the same thing.
Why is the change taking so long?
What is particularly interesting is that the draft law has now been in the parliamentary process for months.
The hearing already took place in January.
Nevertheless, the law was not finalized before the 2026 parliamentary summer break.
The fact that the issue is still being intensely debated is also evidenced by the Bundestag's lobbying register. As of mid-August 2026, 29 regulatory initiatives and 32 position papers or expert opinions regarding the draft law were listed there; the most recent reference was registered as late as August 14.
The debate is therefore by no means over.
And it now revolves less around the fundamental question of whether medical cannabis may be prescribed.
Instead, it is about how low-threshold this access should be.
The focus is increasingly on the online prescription
This is likely the core of the political discussion.
Cannabis as a medicine is not being fundamentally questioned.
Instead, what is being criticized is a model in which there is sometimes very little standing between the desire for cannabis and the issuance of a private prescription.
The problem from the critics' perspective is therefore less:
Telemedicine.
But rather:
How much medicine is actually involved in the telemedical process?
That is an important distinction.
A video consultation with a detailed anamnesis and medical decision is different from a largely automated process that runs almost exclusively via a digital questionnaire.
This is precisely the boundary around which a large part of the further political discussion is likely to revolve.
Telemedicine is nevertheless not automatically bad medicine
This, too, is part of a nuanced view.
Digital medicine has real advantages.
People with limited mobility can reach doctors more easily.
Patients in rural areas gain access to specialized practices.
Long travel distances can be eliminated.
And other areas of medicine have long been using video consultations.
Therefore, it would be too simple to view the current debate as a battle between "real doctors" and "internet medicine."
Even within the parliamentary process, there is a discussion about whether actual digital doctor-patient contact, combined with secure identification, could be a sensible alternative.
The transcript of the Health Committee's hearing explicitly addresses the possibility of a video consultation combined with identity verification such as an eID or comparable procedures.
This suggests a much more interesting question:
Is the goal ultimately really to stop telemedicine – or is it mainly against cannabis prescriptions without real doctor contact?
The situation regarding shipping is also controversial
The situation is similar with the planned shipping ban.
The Federal Ministry of Health is currently holding onto it.
At the same time, there is significant resistance from parts of the industry and the health sector.
As recently as August 2026, a position paper by the industry association Cannabiswirtschaft was published in the Bundestag, explicitly demanding the maintenance of shipping options and telemedical prescriptions for self-payers.
Other submissions also advocate leaving the choice between in-person treatment and video consultation more to the doctor's discretion and allowing pharmacies to continue choosing between on-site dispensing and shipping.
What the final compromise might look like therefore remains open.
Medical cannabis is at a turning point
Regardless of the concrete outcome, the debate shows something fundamental.
The extraordinarily easy accessibility that has developed in parts of the self-pay market since 2024 is increasingly being questioned politically.
This could move medical cannabis back more strongly toward a classic medical model:
Diagnosis. Doctor discussion. Therapeutic decision. Follow-up. Pharmacy.
That would be a clear distinction from a market in which a prescription sometimes appears to be the access key to a regular cannabis product.
And perhaps this very distinction is important in the long term.
Because cannabis can be both medicine and a recreational substance at the same time.
It should just be clear which area is currently being discussed.
What does all this have to do with home growing?
At first glance, very little.
The Medicinal Cannabis Act and private home cultivation are two different areas.
Exactly why it’s interesting.
While there is debate about stricter rules for medical cannabis, private home cultivation remains fundamentally possible under the Cannabis Act.
Adults who have had their residence or habitual abode in Germany for at least six months are permitted to grow up to three cannabis plants at a time for personal consumption at that location.
The proposed amendment to the MedCanG changes nothing about this.
A potential ban on telemedicine or mail-order delivery is therefore not a ban on home growing.
However, home growing is no substitute for medical treatment
This distinction is crucial.
Anyone who needs cannabis due to an illness should not simply replace medical therapy with private home cultivation.
Doctor-supervised treatment has a different goal than cannabis for private consumption.
Dosage, interactions, existing conditions, other medications, and individual risks are matters that belong in medical hands.
The interesting development therefore primarily concerns another area.
People whose interest in cannabis is not primarily medical.
And precisely there is where the political development regarding online prescriptions could change things in the long term.
The unusual situation since 2024
Since partial legalization, Germany has created an interesting juxtaposition.
On one side:
private home cultivation for adults.
On the other:
a very low-threshold out-of-pocket market for medicinal cannabis.
This has created a gray area in public perception.
Not necessarily legally.
But culturally.
Some people engage with cannabis through plants and home growing.
Others through pharmacies.
Others through cannabis clubs.
And still others came to the topic via telemedicine platforms.
As a result, the medical and non-medical cannabis markets have run unusually close to each other in some places.
Tightening the MedCanG could separate these areas more clearly once again.
This could even change home growing culturally
Because home growing means something different than finished cannabis flower from a pharmacy.
Anyone who grows their own inevitably engages with the plant.
With genetics. With seeds. With different strains. With growth. With origin.
And at some point, perhaps even with the question of why two plants of the same variety can look different.
Cannabis thus turns into botany.
And a product becomes a plant with a genetic background.
This is exactly where a difference lies that is often lost in current discussions.
Home growing makes genetics visible
Before partial legalization, many people knew strain names, sure.
But only a smaller portion really concerned themselves with what was behind them.
Anyone selecting their own plants today, however, quickly runs into questions like:
What does feminized mean?
What distinguishes autoflower from photoperiodic genetics?
What is a breeder?
Which parents does a strain have?
Why are there different versions of similar genetics?
What is a phenotype?
Where do Haze, Kush, Skunk, or modern Cookies genetics come from?
This changes the view of cannabis.
A name on a pharmacy list and cannabis genetics are not the same thing.
Home growing makes this difference visible.
From cannabis product back to the cannabis plant
Perhaps this is one of the most interesting developments of German partial legalization.
For decades, cannabis was spoken of mainly as a substance.
THC. Grams. Possession amount. Consumption. Legality.
With home growing, the plant is suddenly back in the picture.
People are engaging with leaves. Growth patterns. Genetics. Breeding. Terpenes. Seeds. And the history of individual strains.
Cannabis is thus regaining a cultural dimension that is barely visible in a discussion purely about consumption or medical supply.
And that is exactly why 2026 could be an important year for home growing
Not because medical cannabis is disappearing.
That doesn't currently appear to be the case.
And not because everyone is suddenly going to start growing their own.
But because the various areas of the cannabis world might sort themselves out more clearly.
Medical cannabis is becoming more medical again. Home growing remains home growing.
That sounds banal.
But it isn't.
Because the clearer this distinction becomes, the more strongly an independent German growing culture can develop.
A culture where it is not just about obtaining cannabis as easily as possible.
But about engaging with the plant itself.
The seed market should also mature as a result
The first wave of home growing after partial legalization was naturally characterized by beginner questions.
Which seeds? Which light? Which soil? Autoflower or feminized? How big will the plant get?
That is completely normal.
With every season, however, the community gains experience.
Beginners become growers.
And growers eventually start asking different questions.
No longer just:
Which cannabis seeds do I need?
But rather:
Which genetics do I want to grow?
Then breeders suddenly become relevant.
Parent lines. Selections. Classics. US genetics. Autoflower specialists. Old European seed banks. Boutique projects.
And it is precisely at this point that culture slowly emerges from a young market.
A prescription tells you little about the origin
An interesting consequence of this development could be that cannabis genetics are perceived more strongly.
With finished flower, many people are initially interested in the product.
With seeds, the decision must be made beforehand.
Which genetics? Which breeder? Which strain? Which properties? Which origin?
This forces a different engagement with cannabis.
You are not presented with the finished plant.
You choose its genetic foundation.
And that is exactly why, culturally, home growing belongs to a different part of the cannabis world than the medical mail-order market.
Cannabis as medicine and cannabis culture do not have to be opponents
This distinction explicitly does not mean playing one area against the other.
Medical cannabis has an important function for patients.
Telemedicine can improve medical care.
Pharmacies fulfill a different task than grow shops, seed banks, or cannabis clubs.
And home growing, in turn, follows a different logic.
It only becomes problematic when these areas blur together so much that no one knows what is actually being discussed anymore.
Is cannabis a medicine? A stimulant? A plant? A hobby? Culture?
The answer is:
It can be all of that. But not always all at the same time.
What will happen in the autumn of 2026?
The decisive political phase will likely begin after the parliamentary summer recess.
The draft law is still in progress, and the topic is being discussed intensively at several levels. Even in mid-August, new activities concerning the MedCanG were being documented in the Bundestag’s lobby register.
Various outcomes are conceivable.
The original government draft could be passed.
It could be changed.
Video consultations could be maintained under stricter conditions.
A compromise could be reached regarding mail-order delivery.
Or the process could drag on further.
Anything else would be speculation at the moment.
For patients and consumers, this primarily means:
Do not confuse headlines with current law.
What can be said today, however
As of August 2026, three things are relatively clear:
First
The federal government wants to more strictly regulate the very low-threshold prescription of medicinal cannabis flowers.
Second
The specific implementation remains politically contentious and has not yet been decided.
Third
Private home cultivation for adults under the Cannabis Act is not currently affected by this.
And it is precisely this third point that is likely to become increasingly interesting outside of the political discussion.
Homegrowing needs no medical justification
Perhaps this is even the most important insight.
Cannabis does not have to be treated as medicine in order for one to engage seriously with the plant.
Since partial legalization, Germany has had its own legal space for this.
Adults can engage in private home cultivation within the legal limits.
With genetics. With breeders. With different strains. With the plant itself.
This is not a medical detour.
It is a distinct part of the new cannabis reality.
From acquisition to engagement
This is precisely where a cultural shift could occur in the long term.
The question then no longer is exclusively:
How can I get hold of cannabis as easily as possible?
But rather:
What do I actually want to grow?
Where does this genetics come from? Who bred it? Why did this strain become known? What old genetics are in it? What distinguishes an established breeder from a short-term hype?
These are completely different questions.
And perhaps it is precisely these questions that will allow a cannabis culture to mature.
Medicine under pressure, homegrowing in the second chapter
The political debate over medical cannabis will likely continue for some time.
And it is important.
Patients need a reliable supply.
Telemedicine should function where it is medically sensible.
At the same time, it is legitimate to discuss how medical prescriptions are obtained and where the line lies between medical treatment and a de facto automated access to cannabis.
For homegrowing, however, this discussion is only indirectly relevant.
Because private home cultivation now has its own foundation.
And perhaps this is precisely why a second phase is beginning after the great legalization excitement of 2024.
In 2024, the question was:
Are we allowed to grow now?
In 2026, it is increasingly:
What are we actually growing – and why?
That is a big difference.
FAQ: Medical cannabis, telemedicine and homegrowing 2026
Will cannabis telemedicine be banned in 2026?
Not so far. The government's draft provides for personal contact in a practice or a home visit for the initial prescription of cannabis flowers. For follow-up prescriptions, telemedicine is to remain possible under certain conditions. As of August 22, 2026, the draft has not yet been passed.
Will the shipping of medical cannabis be banned?
The current government draft provides for a ban on shipping medical cannabis flowers. Pharmacy courier services are to remain possible. This change, too, is not yet in effect.
Is it still allowed to grow cannabis privately in 2026?
Yes. Adults with at least six months of residence or habitual abode in Germany are currently allowed to cultivate up to three cannabis plants at the same time for personal consumption at their residence or habitual abode.
Does the planned MedCanG amendment affect private home cultivation?
The current bill concerns the Medical Cannabis Act and in particular the prescription and dispensing of cannabis flowers for medical purposes. The existing rules for private home cultivation under the Cannabis Act are not repealed by this.
Is homegrowing an alternative to medical cannabis?
Not in a medical sense. Anyone who needs cannabis for the treatment of an illness should discuss therapy decisions with their doctors. Private home cultivation for personal use and medical cannabis therapy are legally and content-wise different areas.
Why could homegrowing become more important anyway?
The more clearly medical care and non-medical cannabis consumption are separated from each other, the more strongly private home cultivation could be perceived as a separate part of German cannabis culture. In this context, topics like genetics, strains, breeders, and plant knowledge are moving more into the foreground.
Conclusion: Perhaps cannabis is once again becoming just a plant
The discussion about medical cannabis is currently revolving primarily around access.
How simple should a prescription be? Does a doctor have to be seen in person? Is a video consultation sufficient? Are pharmacies allowed to continue shipping cannabis flowers?
These are questions that politics, medicine, and society must answer.
Homegrowing, on the other hand, poses a different question.
Which plant do I actually want to grow?
And therein lies perhaps one of the most exciting consequences of partial legalization.
Cannabis is no longer viewed exclusively as a forbidden substance.
Not exclusively as a medicine.
And also not exclusively as a finished product.
For a growing homegrow culture, cannabis is becoming once again what it originally always was:
A plant with genetics, origin, and history.
Whether the rules for medical cannabis are actually tightened will only become apparent in further parliamentary proceedings.
That an independent homegrowing and genetics culture is developing in parallel in Germany, however, is already a reality.
And perhaps that is exactly the development that will last longer in the end than the current discussion about the prescription.
Medical cannabis is under political pressure in 2026, but homegrowing remains a distinct part of the German cannabis reality. Perhaps this is exactly what makes it clearer what private home cultivation is really about: not a medical detour, but plant knowledge, genetics, origin, breeders, and a new growing culture that understands cannabis once again as a plant.
